Adenosine A2A receptor antagonists in Parkinson's disease: still in the running
Authors:
- 1 August 2014
- journal article
- editorial
- Published by Elsevier in The Lancet Neurology
- Vol. 13 (8) , 748-749
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trialThe Lancet Neurology, 2014
- Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's diseaseMovement Disorders, 2013
- Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trialsMovement Disorders, 2012
- Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 studyParkinsonism & Related Disorders, 2012
- Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trialThe Lancet Neurology, 2011
- A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulationJournal of Neurology, 2010
- Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trialThe Lancet, 2005
- A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s diseaseExperimental Neurology, 2003
- Low‐dose L‐dopa therapy in Parkinson's diseaseNeurology, 1986